Xeris Biopharma Holdings Inc. Stock
Xeris Biopharma Holdings Inc. gained 2.890% today.
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 8 € there is a hugely positive potential of 53.55% for Xeris Biopharma Holdings Inc. compared to the current price of 5.21 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 2.890% | 9.737% | -2.998% | -0.987% | -20.586% | 234.690% | 29.922% |
| Heron Therapeutics Inc. | -0.220% | 4.787% | -31.800% | -66.034% | -38.106% | -50.644% | -94.659% |
| Evolus Inc | -1.120% | -11.458% | -6.077% | -68.807% | -37.615% | -55.844% | -65.313% |
| Sangamo Therapeutics Inc. | 9.330% | -30.535% | -41.893% | -64.349% | -38.736% | -86.757% | -97.993% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat